Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - entecavir monohydrate - film-coated tablet - 1 milligram(s) - nucleoside and nucleotide reverse transcriptase inhibitors; entecavir

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - entecavir - tablet - 0.5 milligram(s) - nucleoside and nucleotide reverse transcriptase inhibitors; entecavir

United States - English - NLM (National Library of Medicine)

avpak - entecavir anhydrous (unii: nnu2o4609d) (entecavir anhydrous - unii:nnu2o4609d) - entecavir is indicated for the treatment of chronic hepatitis b virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (alt or ast) or histologically active disease. none. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to entecavir during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary prospective pregnancy data from the apr are not sufficient to adequately assess the risk of birth defects, miscarriage or adverse maternal or fetal outcomes. entecavir use during pregnancy has been evaluated in a limited number of individuals reported to the apr and the number of exposures to entecavir is insufficient to make a risk assessment compared to a reference population. the estimated background rate for major birth

United States - English - NLM (National Library of Medicine)

florida pharmaceutical products, llc - entecavir (unii: 5968y6h45m) (entecavir anhydrous - unii:nnu2o4609d) - entecavir tablets usp are indicated for the treatment of chronic hepatitis b virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (alt or ast) or histologically active disease. none. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to entecavir during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary prospective pregnancy data from the apr are not sufficient to adequately assess the risk of birth defects, miscarriage or adverse maternal or fetal outcomes. entecavir use during pregnancy has been evaluated in a limited number of individuals reported to the apr and the number of exposures to entecavir is insufficient to make a risk assessment compared to a reference population. the estimated background rate fo

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis uk limited - entecavir monohydrate - film coated tablet - 0.5 milligram - nucleoside and nucleotide reverse transcriptase inhibitors

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis uk limited - entecavir monohydrate - film coated tablet - 1 milligram - nucleoside and nucleotide reverse transcriptase inhibitors

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - entecavir monohydrate - tablet - 500microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - entecavir monohydrate - tablet - 1mg

Malta - English - Medicines Authority

pharos – pharmaceutical oriented services limited lesvou str. (end), thesi loggos, industrial zone, 144 52 metamorfossi attikis,, greece - entecavir hydrate - film-coated tablet - entecavir hydrate 0.5 mg - antivirals for systemic use

Malta - English - Medicines Authority

pharos – pharmaceutical oriented services limited lesvou str. (end), thesi loggos, industrial zone, 144 52 metamorfossi attikis,, greece - entecavir hydrate - film-coated tablet - entecavir hydrate 1 mg - antivirals for systemic use